Print PDF

Patent Litigation - Arbitration and Other ADR

A major European research institute, represented by Finnegan, has been embroiled in a three year dispute with a major U.S. pharmaceutical company involving patent inventorship and contract interpretation issues.  The three-member arbitration panel has ruled in favor of our client which is now entitled to increased license fees from the pharmaceutical partner.
In decisions from the U.S. Federal Circuit Court of Appeals, U.S. District Court for the Northern District of Illinois, and the American Arbitration Association (AAA), Finnegan successfully prevented a larger competitor from manufacturing or selling a generic version of Finnegan client Cumberland Pharmaceuticals’ flagship product, Acetadote®, a life-saving intravenous formulation of acetylcysteine for the treatment of acetaminophen overdose. Cumberland’s current patent-protected formulation is free of the EDTA chelating agent, which is an improvement over earlier formulations sold by Cumberland and others. First, in the AAA decision, the arbitrator issued a final award in favor of Cumberland enjoining the competitor and further awarded attorney’s fees and costs to Cumberland. Second, in the Abbreviated New Drug Application (ANDA) district court case, following claim construction rulings favorable to Cumberland, the generic company conceded infringement. A trial proceeded on the generic’s three validity attacks—derivation, anticipation, and obviousness—which were all rejected by the presiding judge. Finally, in response to the generic’s appeal of the district court’s decision, the Federal Circuit further considered and expressly rejected the generic’s validity attacks. The Federal Circuit’s affirmance of the district court’s ruling thus confirms Cumberland’s patent protection for ten years.
Finnegan represented CSL Behring in an ex parte reexamination and corresponding arbitration proceeding against Baxter and Bayer relating to Factor VIII blood products, securing a favorable settlement for our client.